Arecor Therapeutics PLC (AIM:AREC) has received a European patent (EP3618840) for its fast-acting insulin products, AT278 and AT247, further protecting the intellectual property underpinning their unique formulations.
This development follows the company's recent patent acquisitions in Australia, India, and Mexico.
Arecor's chief scientific officer, Jan Jezek, said: "We continue to build a strong intellectual property portfolio in key markets for our ultra-fast acting insulin products, AT278 and AT247, which provide the group significant growth potential in a multi-billion dollar market driven by the need for tighter glucose control and the rise of innovative delivery devices and digital technologies."
He pointed out that AT278, Arecor's 'disrupter insulin' with its high concentration and ultra-rapid profile, has the potential to be the gold standard insulin for the growing population of people with high daily insulin needs.
Jezek added that data to support its profile are expected in the first half.